MRTX / Mirati Therapeutics, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

MRTX / Mirati Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

MRTX / Mirati Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

MRTX / Mirati Therapeutics, Inc. / Avoro Capital Advisors LLC - MIRATI THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh

MRTX / Mirati Therapeutics, Inc. / RTW INVESTMENTS, LP - MIRATI THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs

AGREEMENT

EX-99.1 2 tm242424d27ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Mirati Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2024 BAKER BROS. AD

MRTX / Mirati Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Mirati Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 60468T105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file

MRTX / Mirati Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 60468T105 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35921 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified

MRTX / Mirati Therapeutics, Inc. / Boxer Capital, LLC Activist Investment

SC 13D/A 1 ff295284713da19-mirati.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 19)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 60468T105 (CUSIP Number) Josh La Grange Fried, Frank, Harris, Shriver & Jacobson LLP 801 17th Street, NW, Washi

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

EX-99.25

Form 25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-207848 THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (Exact name of Registrant as specified in its c

Registration No. 333-207848 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-207848 UNDER THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-2693615 (State or jurisdiction of incorporation or organization) (I.R.S. Employer Identificat

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MIRATI THERAPEUTICS, INC. ARTICLE ONE

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MIRATI THERAPEUTICS, INC. ARTICLE ONE The name of the corporation is Mirati Therapeutics, Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at that address

AMENDED AND RESTATED MIRATI THERAPEUTICS, INC. A Delaware Corporation ARTICLE I

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MIRATI THERAPEUTICS, INC. A Delaware Corporation ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be located at 251 Little Falls Drive, Wilmington, Delaware 19808, in the County of New Castle. The name of the corporation’s registered agent at such address shall be Corporation Service

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

CONTINGENT VALUE RIGHTS AGREEMENT

Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 23, 2024 (this “Agreement”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent (as defined herein). Capitalized terms used but not defined herein shall hav

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-257636 THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (Exact name of Registrant as specified in its c

Registration No. 333-257636 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-257636 UNDER THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-2693615 (State or jurisdiction of incorporation or organization) (I.R.S. Employer Identificat

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT NO. 333-191544 FORM S-1 REGISTRATION STATEMENT NO. 333-191872 THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC.

Registration No. 333-191544 Registration No. 333-191872 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT NO. 333-191544 FORM S-1 REGISTRATION STATEMENT NO. 333-191872 UNDER THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-2693615 (State or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT NO. 333-191544 FORM S-1 REGISTRATION STATEMENT NO. 333-191872 THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC.

Registration No. 333-191544 Registration No. 333-191872 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT NO. 333-191544 FORM S-1 REGISTRATION STATEMENT NO. 333-191872 UNDER THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-2693615 (State or

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 MIRATI THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

As filed with the Securities and Exchange Commission on January 23, 2024

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.

MRTX / Mirati Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T105 (CUSIP Number) December 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 MIRATI THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Transaction Value (in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 MIRATI THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure SAN DIEGO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 MIRATI THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

Position and Compensation Adjustment Letter, dated August 23, 2023, by and between

Exhibit 10.7 August 23, 2023 Aaron Ondrey [email protected] Subject: Position and Compensation Adjustment Dear Aaron: The purpose of this letter is to confirm the changes to your position and compensation as discussed. In connection with your appointment as Interim Chief Financial Officer (“CFO”) effective September 8, 2023, your annualized base salary is increased to $450,000. Additionally, you

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MIRATI THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Consulting Agreement, dated September 9, 2023, by and between

Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is effective on September 9, 2023 (the “Effective Date”) by and between MIRATI THERAPEUTICS, INC., a Delaware corporation with principal offices at 3545 Cray Court, San Diego, CA 92121 (the “Company”) and LAURIE STELZER, an individual residing at 6125 N. 31st Ct., Phoenix, AZ 85016 (“Consultant”). Company and Consultant

Consulting Agreement Amendment No 1., dated September 12, 2023, by and between

Exhibit 10.3 AMENDMENT NO. 1 TO THE CONSULTING AGREEMENT BETWEEN MIRATI THERAPEUTICS, INC, and LAURIE STELZER This Amendment No. 1 (the “Amendment”) is effective as of September 12, 2023 (the “Amendment Date”) by and between Mirati Therapeutics, Inc. (“Mirati”) and Laurie Stelzer (“Consultant”). Mirati and Consultant are hereinafter individually referred to as “Party” and collectively referred to

Separation Agreement and Release, dated August 7, 2023, by and between

Exhibit 10.1 August 7, 2023 David Meek Re: Separation Agreement Dear David: This letter sets forth the substance of the separation agreement (the “Agreement”) that Mirati Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation; Final Pay. In connection with a mutual separation, you hereby submit, and the Company accepts, your resignation as Chief Ex

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates SAN DIEGO – November 6, 2023 – Mirati Therapeutics, Inc.

Employment Agreement, dated June 29, 2022, by and between

Exhibit 10.5 29-Jun-2022 Aaron Ondrey Re: Offer of Employment Dear Aaron: Mirati Therapeutics, Inc. is pleased to offer you at-will employment in the exempt position of SVP, Financial Planning & Analysis and Facilities on the terms and conditions set forth in this offer letter ("Offer"). This Offer is conditioned on, and subject to, satisfactory proof of your identity and right to work in the Unit

for Senior Vice Presidents and Vice Presidents

Exhibit 10.6 Mirati Therapeutics, Inc. Severance Policy for Senior Vice Presidents and Vice Presidents This severance policy for Senior Vice Presidents and Vice Presidents (the “Policy”) refers to any circumstance under which a Senior Vice President or Vice President ceases to be part of Mirati Therapeutic, Inc.'s (the "Company") workforce. This Policy replaces, in its entirety, any prior severanc

Consulting Agreement Amendment No 2., dated September 22, 2023, by and between

Exhibit 10.4 AMENDMENT NO. 2 TO THE CONSULTING AGREEMENT BETWEEN MIRATI THERAPEUTICS, INC, and LAURIE STELZER This Amendment No. 2 (the “Amendment”) is effective as of September 22, 2023 (the “Second Amendment Date”) by and between MIRATI THERAPEUTICS, INC. (“Mirati”) and LAURIE STELZER (“Consultant”). Mirati and Consultant are hereinafter collectively referred to as “Parties.” WHEREAS, the Partie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFM14A 1 edge20012673x2defm14a.htm DEFM14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐ Definitive Proxy Statement  ☐ Definitive Additional Materials  ☐ Soliciting Material Pursuant to §240.

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Mirati Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fe

Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Mirati Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

MRTX / Mirati Therapeutics Inc / Boxer Capital, LLC Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

ARTICLE XV

Exhibit 3.2 This exhibit demonstrates amendments made to the Existing Forum Selection Provision by the Forum Selection Amendment. New language is underlined and deleted language is stricken through. ARTICLE XV MISCELLANEOUS Section 47. Forum for Adjudication of Certain Disputes. Unless the corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), th

AGREEMENT AND PLAN OF MERGER MIRATI THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and VINEYARD MERGER SUB INC., a Delaware corporation Dated as of October 8, 2023

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: MIRATI THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and VINEYARD MERGER SUB INC., a Delaware corporation Dated as of October 8, 2023 Table of Contents Section 1 MERGER TRANSACTION 1.1 Merger of Merger Sub into the Company 3 1.2 Effect of the Merger 3 1.3 Closing; Effective Time 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(

AMENDMENT TO MIRATI THERAPEUTICS, INC. ARTICLE XV

Exhibit 3.1 AMENDMENT TO BYLAWS OF MIRATI THERAPEUTICS, INC. ARTICLE XV MISCELLANEOUS Section 47.     Forum for Adjudication of Certain Disputes. Unless the corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), the Delaware Court of Chancery shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of th

Exhibit demonstrating amendments made to the Existing Forum Selection Provision by the Forum Selection Amendment

Exhibit 3.2 This exhibit demonstrates amendments made to the Existing Forum Selection Provision by the Forum Selection Amendment. New language is underlined and deleted language is stricken through. ARTICLE XV MISCELLANEOUS Section 47. Forum for Adjudication of Certain Disputes. Unless the corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), th

Amendment to Bylaws (incorporated by reference to Mirati Therapeutics, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 10, 2023).

Exhibit 3.1 AMENDMENT TO BYLAWS OF MIRATI THERAPEUTICS, INC. ARTICLE XV MISCELLANEOUS Section 47.     Forum for Adjudication of Certain Disputes. Unless the corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), the Delaware Court of Chancery shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2023 MIRATI THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2023 MIRATI THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Empl

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Conti

Exhibit 99.1 FOR IMMEDIATE RELEASE Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S.

Agreement and Plan of Merger, dated as of October 8, 2023, by and among Bristol-Myers Squibb Company, Vineyard Merger Sub Inc., and Mirati Therapeutics, Inc.*

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: MIRATI THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and VINEYARD MERGER SUB INC., a Delaware corporation Dated as of October 8, 2023 Table of Contents Section 1 MERGER TRANSACTION 1.1 Merger of Merger Sub into the Company 3 1.2 Effect of the Merger 3 1.3 Closing; Effective Time 3

VOTING AND SUPPORT AGREEMENT

Exhibit 99.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”), dated as of October 8, 2023, is entered into by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and the stockholders of Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), listed on Exhibit A hereto (each, a “Stockholder” and collectively, the “Stockholders”). Ca

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Conti

Exhibit 99.1 FOR IMMEDIATE RELEASE Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S.

VOTING AND SUPPORT AGREEMENT

Exhibit 99.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”), dated as of October 8, 2023, is entered into by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and the stockholders of Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), listed on Exhibit A hereto (each, a “Stockholder” and collectively, the “Stockholders”). Ca

As filed with the Securities and Exchange Commission on October 5, 2023

S-8 As filed with the Securities and Exchange Commission on October 5, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirati Therapeutics, Inc.

Second Amendment to Mirati Therapeutics, Inc. Inducement Plan

Exhibit 99.3 SECOND AMENDMENT TO MIRATI THERAPEUTICS, INC. INDUCEMENT PLAN A. Mirati Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s Inducement Plan (as previously amended, the “Plan”); B. The Plan currently provides for 1,417,343 shares of Common Stock to be reserved for issuance under the Plan; and C. The Company now

MRTX / Mirati Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T105 (CUSIP Number) September 22, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer

Exhibit 99.1 Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer SAN DIEGO, Calif., August 23, 2023 /PRNewswire/ - Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity. Aaron Ondrey, senior vice p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 MIRATI THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Empl

MRTX / Mirati Therapeutics Inc / Boxer Capital, LLC Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Agreement, dated August 15, 2023 among Boxer Capital, Boxer Management, Braslyn, MVA Investors, Lockend Five, Joe Lewis, Aaron I. Davis, Shehan B. Dissanayake and Christopher Fuglesang.

EX-1 2 ff239249113da17-ex1.htm JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Mirati Therapeutics, Inc. and further agree that this Joint Fi

9,669,631 Shares of Common Stock Pre-Funded Warrants to Purchase 1,121,736 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257636 Prospectus Supplement (To Prospectus dated July 2, 2021) 9,669,631 Shares of Common Stock Pre-Funded Warrants to Purchase 1,121,736 Shares of Common Stock We are offering 9,669,631 shares of our common stock, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock. The purchase

Underwriting Agreement, dated as of August 8, 2023, by and between Mirati Therapeutics, Inc. and Goldman Sachs & Co. LLC. (incorporated by reference to Exhibit 1.1. to the registrants Current Report on Form 8-K filed with the SEC on August 9, 2023)

EX-1.1 Exhibit 1.1 9,669,631 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,121,736 Shares of Common Stock MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT August 8, 2023 Goldman Sachs & Co. LLC As Representatives of the several underwriters c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Ladies and Gentlemen: Introductory. Mirati Therapeutics, Inc., a Delaware c

Calculation of Filing Fee Tables (Form Type) Mirati Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward R

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Mirati Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 MIRATI THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emplo

MIRATI THERAPEUTICS ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING

EX-99.2 Exhibit 99.2 MIRATI THERAPEUTICS ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING SAN DIEGO, August 8, 2023 — Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced the pricing of an underwritten public offering of 9,669,631 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to pur

MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

EX-99.1 Exhibit 99.1 MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING SAN DIEGO, August 8, 2023 — Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced that it intends to offer and sell $250.0 million of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offerin

Form of Pre-Funded Warrant.

EX-4.1 Exhibit 4.1 MIRATI THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares:[ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 2023 Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (th

Forward Looking Statements and Disclaimers This presentation includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial ® potential of KRAZATI (adagrasib), MRTX1719 (MTA cooperative PRMT5 in

EX-99.3 Exhibit 99.3 Mirati Presentation August 2023 1 Forward Looking Statements and Disclaimers This presentation includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial ® potential of KRAZATI (adagrasib), MRTX1719 (MTA cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective G12D KRAS inhibitor), Mirati’s tec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registrant as

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥

EX-99.1 Exhibit 99.1 Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and ea

Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek Charles M. Baum, M.D., Ph.D. assumes role of interim CEO

EX-99.2 Exhibit 99.2 Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek Charles M. Baum, M.D., Ph.D. assumes role of interim CEO SAN DIEGO, Calif., August 8, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company today announced that David Meek and the Company mutually agreed for Mr. Meek to step down from his role as CEO

Employment Agreement, dated April 12, 2023, by and between the Registrant and John B. Moriarty, Jr.

April 12, 2023 John Moriarty 208 Benson Circle Mill Valley, CA 94941 Re: Offer of Employment Dear John: Mirati Therapeutics, Inc.

Non-Employee Director Compensation Policy, Amended and Restated June 22, 2023.

Exhibit 10.2 MIRATI THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY AMENDED AND RESTATED: June 22, 2023 (“Effective Date”) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in thi

Subject to Completion, dated August 8, 2023

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257636 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities and are not soliciting an offer to buy the securities in any jurisdiction where the offer or sale is not permitted.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 MIRATI THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 MIRATI THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employ

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced

EX-99.1 Exhibit 99.1 Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation SAN DIEGO, Calif., USA and ZUG, Switzerland, July 21, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the European

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 MIRATI THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 MIRATI THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® SAN DIEGO, May 24, 2023 /PRNewswire/ - Mirati Therapeutics, Inc.

As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 MIRATI THERAPEUTICS, INC. (E

As filed with the Securities and Exchange Commission on May 12, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirati Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MIRATI THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

2013 Employee Stock Purchase Plan, as amended.

MIRATI THERAPEUTICS, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: May 8, 2013 APPROVED BY THE STOCKHOLDERS: June 21, 2013 AMENDED AND APPROVED BY THE BOARD OF DIRECTORS: September 22, 2022 APPROVED BY THE STOCKHOLDERS: May 11, 2023 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registrant as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 MIRATI THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employer

Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates SAN DIEGO – May 9, 2023 – Mirati Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin

Non-Employee Director Compensation Policy

Exhibit 10.14 MIRATI THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Updated January 6, 2023) (“Effective Date”) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35921 MIRATI THERAPE

Employment Agreement, dated August 17, 2022, by and between the Registrant and Alan Sandler, M.D.

Exhibit 10.33 August 17, 2022 Alan Sandler 22 Arana Circle Sausalito, CA 94965 Re: Offer of Employment Dear Alan: Mirati Therapeutics, Inc. (the “Company” or “Mirati”) is pleased to offer you at-will employment in the position of Chief Medical Officer on the terms and conditions set forth in this letter agreement (the “Agreement”). Certain capitalized terms used in this Agreement have the meanings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MIRATI THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates SAN DIEGO – February 28, 2023 – Mirati Therapeutics, Inc.

Letter Agreement, dated December 16, 2022, by and between the Registrant and James Christensen.

Exhibit 10.32 December 16, 2022 James Christensen 4276 Kerwood Court San Diego, CA 92130 Subject: Special Cash Award Dear Jamie, I am pleased to share with you that the Compensation Committee of the Board of Directors of Mirati Therapeutics, Inc. (“Mirati”) has approved your eligibility for a one-time special lump sum cash bonus (“Special Cash Award”) in a total amount of $1,000,000, subject to th

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiary Country of Origin MethylGene Inc. Canada Mirati Therapeutics B.V. Netherlands Mirati Therapeutics (Suisse) GmbH Switzerland

MRTX / Mirati Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d403321dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T 105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement

MRTX / Mirati Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G 1 armistice-mrtx123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the

MRTX / Mirati Therapeutics Inc / RTW INVESTMENTS, LP - MIRATI THERAPEUTICS, INC. Passive Investment

SC 13G 1 p23-0579sc13g.htm MIRATI THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Ch

MRTX / Mirati Therapeutics Inc / Avoro Capital Advisors LLC - MIRATI THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p23-0269sc13ga.htm MIRATI THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check

AGREEMENT

EX-99.1 2 d403321dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

MRTX / Mirati Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01433-miratitherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Mirati Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 60468T105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box t

MRTX / Mirati Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 60468T105 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate

Forward Looking Statement This presentation includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and TM commercial potential of KRAZATI (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (M

EX-99.1 Exhibit 99.1 NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer st 41 Annual J.P. Morgan Healthcare Conference January 9, 2023 1 Forward Looking Statement This presentation includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and TM commercial potential of KRAZATI (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 MIRATI THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Empl

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI

EX-99.1 Exhibit 99.1 Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation SAN DIEGO, December 12, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Mirati Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Mirati Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 MIRATI THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic

EX-99.1 Exhibit 99.1 Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) • Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutation • Findin

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Ch

Exhibit 99.1 Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibitor Therapy SAN DIEGO, Dec. 2, 2022 /PRNewswire/ ? Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted onc

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Mirati Therapeutics, Inc. Executive

Mirati Therapeutics, Inc. Executive Severance Plan This severance Plan (the "Plan") refers to any circumstance under which the undersigned (each referred to herein as ?you,? ?your?, ?Employee? or a ?Participant?) ceases to be part of Mirati Therapeutics, Inc.'s (the "Company"). This Plan replaces, in its entirety, any prior severance agreements, policies, understanding, or plans, agreed to by you

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registran

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a dec

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO, Nov. 8, 2022 /PRNewswire/ - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical

Mirati Therapeutics, Inc. Consolidated Balance Sheets (in thousands) September 30, December 31, 2022 2021 Assets Current assets Cash, cash equivalents and short-term investments $ 1,200,992 $ 1,491,340 Other current assets 24,792 16,643 Total current

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates SAN DIEGO ? November 8, 2022 ? Mirati Therapeutics, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer Adagrasib demonstrates promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in

Exhibit 99.1 Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer Adagrasib demonstrates promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation SAN DIEGO, Sept. 7, 2022/PRNewswire/ ? M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registrant as

Employment Agreement, dated April 7, 2022, by and between the Registrant and Laurie D. Stelzer

March 29, 2022 (Revised April 7, 2022) Laurie Stelzer 6125 N. 31st CT Phoenix, AZ. 85016 Re: Offer of Employment Dear Laurie: Mirati Therapeutics, Inc. (the ?Company? or ?Mirati?) is pleased to offer you at-will employment in the position of Chief Financial Officer on the terms and conditions set forth in this letter agreement (the ?Agreement?). Certain capitalized terms used in this Agreement hav

Mirati Therapeutics, Inc. Consolidated Balance Sheets (in thousands) June 30, December 31, 2022 2021 Assets Current assets Cash, cash equivalents and short-term investments $ 1,181,328 $ 1,491,340 Other current assets 21,598 16,643 Total current asse

Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates SAN DIEGO ? August 3, 2022 ? Mirati Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emplo

As filed with the Securities and Exchange Commission on July 15, 2022

As filed with the Securities and Exchange Commission on July 15, 2022 Registration No.

Amendment to Mirati Therapeutics, Inc. Inducement Plan

Exhibit 99.4 AMENDMENT TO MIRATI THERAPEUTICS, INC. INDUCEMENT PLAN A. Mirati Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, (the ?Company?) established the Company?s Inducement Plan (the ?Plan?); B. The Plan currently provides for 417,343 shares of Common Stock to be reserved for issuance under the Plan; and C. The Company now wishes to amend the Plan to incr

Filing Fee Table

EX-FILING FEES 5 d305464dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirati Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development pl

ASCO Investor Event JUNE 6, 2022 Exhibit 99.1 This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation ada

New Late-Breaking Data on Investigational

Exhibit 99.1 New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases ? Presentation marks first clinical dataset with a KRASG12C-inhibitor in patients with active, untreated CNS metastases SAN DIEGO, June 6, 2022/PRNewswire/ ? Mirati Ther

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

Delivers Positive Results in Registration-Enabling Study of Patients with KRAS

Exhibit 99.1 Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer SAN DIEGO, May 26, 2022/PRNewswire/ ? Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluati

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

2022 Equity Incentive Plan (as approved by the Registrant’s Stockholders May 12, 2022), Form of Stock Option Grant Notice and Stock Option Agreement, Form of RSU Grant Notice with Sell to Cover Election and Award Agreement, and Form of RSU Grant Notice and Award Agreement, thereunder.

Exhibit 99.1 MIRATI THERAPEUTICS, INC. 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 4, 2022 APPROVED BY THE STOCKHOLDERS: MAY 12, 2022 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS UPON CHANGES IN COMMON

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirati Therapeutics, Inc.

As filed with the Securities and Exchange Commission on May 20, 2022

As filed with the Securities and Exchange Commission on May 20, 2022 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Exhibit 99.1 Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer SAN DIEGO ? May 16, 2022 ? Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as the Company?s Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company?s Chief Executive Officer, David Meek. David com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

MIRATI THERAPEUTICS, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: April 4, 2022 Approved by the Stockholders: May 12, 2022

MIRATI THERAPEUTICS, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: April 4, 2022 Approved by the Stockholders: May 12, 2022 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Limitations. 2 4. Options and Stock Appreciation Rights. 3 5. Awards Other Than Options and Stock Appreciation Rights. 7 6. Adjustments upon Changes in Common Stock;

Mirati Therapeutics, Inc. Consolidated Balance Sheets (in thousands) March 31, December 31, 2022 2021 Assets Current assets Cash, cash equivalents and short-term investments $ 1,326,474 $ 1,491,340 Other current assets 16,643 16,643 Total current ass

Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates SAN DIEGO ? May 4, 2022 ? Mirati Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registrant as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 mirati2022proxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as

Amended and Restated Second Amendment to Letter Agreement, effective September 20, 2021, by and between the Registrant and Dr. James Christensen.

Exhibit 10.29 AMENDED AND RESTATED SECOND AMENDMENT TO LETTER AGREEMENT This Amended and Restated Second Amendment to Letter Agreement (this ?Amendment?) is entered into by Mirati Therapeutics, Inc., a Delaware corporation (the ?Company?), and James Christensen, Ph.D. (?Employee? or ?you?) and shall be effective as of September 20, 2021. The purpose of this Amendment is to provide Employee with ce

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiary Country of Origin MethylGene Inc. Canada Mirati Therapeutics B.V. Netherlands

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

Separation Agreement and Release, dated December 15, 2021, by and between the Registrant and Dan Faga.

Exhibit 10.30 October 28, 2021 Revised December 14, 2021 Daniel Faga 1903 El Camino Del Teatro La Jolla, CA 92037 Re: Separation Agreement and Release Dear Dan: This letter sets forth the substance of the separation agreement (the ?Agreement?) that Mirati Therapeutics, Inc. (the ?Company?) is offering to aid in your employment transition. The Agreement shall become effective upon the Effective Dat

Mirati Therapeutics, Inc. Consolidated Balance Sheets (in thousands) December 31, December 31, 2021 2020 Assets Current assets Cash, cash equivalents and short-term investments $ 1,491,340 $ 1,390,106 Other current assets 16,643 13,537 Total current

Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates SAN DIEGO ? February 28, 2022 ? Mirati Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-15803 MIRATI THERAPEUT

Amended and Restated Non-Employee Director Compensation Policy.

Exhibit 10.13 MIRATI THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: SEPTEMBER 9, 2014 EFFECTIVE DATE: SEPTEMBER 9, 2014 AMENDED AND RESTATED: DECEMBER 9, 2015 AMENDED AND RESTATED: MARCH 30, 2017 AMENDED AND RESTATED: JANUARY 18, 2018 AMENDED AND RESTATED: JANUARY 17, 2019 AMENDED AND RESTATED: DECEMBER 12, 2019 AMENDED AND RESTATED: DECEMBER 10, 2020 AM

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics’ New Drug Application for

Exhibit 99.1 ` U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics? New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer SAN DIEGO, February 15, 2022 ? Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug

MRTX / Mirati Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T 105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

MRTX / Mirati Therapeutics Inc / Avoro Capital Advisors LLC - MIRATI THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh

MRTX / Mirati Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Mirati Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 60468T105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

MRTX / Mirati Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development pl

J.P. Morgan Healthcare Conference January 2022 Exhibit 99.1 This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. (?Mirati?). Any statement describing Mirati?s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati?s drug development pipeline, including without

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Mirati Therapeutics Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Mirati Therapeutics Announces Proposed Public Offering of Common Stock 11/09/2021 SAN DIEGO, Nov. 9, 2021 /PRNewswire/ ? Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock. In addition, Mirati expects to grant the underwriters of the

CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par valu

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257636 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par value per share 3,965,516(1) $ 145.00 $574,999,820 $53,302.49 (1) Includes

Underwriting Agreement, dated November 10, 2021.

Exhibit 1.1 3,448,275 Shares of Common Stock MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT November 10, 2021 Goldman Sachs & Co. LLC SVB Leerink LLC Cowen and Company, LLC As Representatives of the several underwriters c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Cowen and Company, LLC 599 Le

Mirati Therapeutics Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Mirati Therapeutics Announces Pricing of Public Offering of Common Stock 11/10/2021 SAN DIEGO, Nov. 10, 2021 /PRNewswire/ ? Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price to the public of $145.00 per share. The aggregate gross proceed

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Subject to Completion, dated November 9, 2021

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257636 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities and are not soliciting an offer to buy the securities in any jurisdiction where the offer or sale is not permitted.

This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development pl

EX-99.1 Corporate Overview Presentation November 2021 Exhibit 99.1 This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including w

Employment Agreement, dated September 17, 2021, by and between the Registrant and David

September 17, 2021 David Meek 258 Edgewater Dr. Gilford, NH 03249 Re: Offer of Employment Dear David: Mirati Therapeutics, Inc. (the ?Company? or ?Mirati?) is pleased to offer you at-will employment in the position of Chief Executive Officer on the terms and conditions set forth in this letter agreement (the ?Agreement?). Certain capitalized terms used in this Agreement have the meanings set forth

Third Amendment to Amended and Restated Employment Agreement, dated September 20, 2021, by and between the Registrant and Dr. Charles M. Baum

THIRD AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This THIRD AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Third Amendment?) is made and entered into effective as of September 20, 2021 (the ?Effective Date?), by and between Mirati Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registran

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Mirati Therapeutics, Inc. Consolidated Balance Sheets (in thousands) September 30, 2021 December 31, 2020 Assets (unaudited) Current assets Cash, cash equivalents and short-term investments $ 1,154,418 $ 1,390,106 Other current assets 17,476 13,537 T

EX-99.1 2 exhibit991-q32021.htm EX-99.1 Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Began submission of the New Drug Application for adagrasib for the treatment of patients with previously treated KRASG12C-mutated non-small cell lung cancer under the Real-Time Oncology Review pilot program SAN DIEGO – November 8, 2021 – Mirati Therapeutics, Inc. (N

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Page 1 of 3

Exhibit 99.3 Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer Company to host Virtual Investor Event on September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO ? September 20, 2021 ? Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announc

1

Exhibit 99.4 Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors SAN DIEGO ? September 20, 2021 ? Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory

Page 1 of 3

EX-99.1 2 d231945dex991.htm EX-99.1 Exhibit 99.1 Mirati Therapeutics Appoints David Meek as Chief Executive Officer Charles M. Baum, M.D., Ph.D to Continue in New Role of President, Founder and Head of Research and Development SAN DIEGO – September 20, 2021 – Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS E

1

Exhibit 99.2 Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRASG12C-Mutated Colorectal Cancer SAN DIEGO ? September 19, 2021 ? Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL-1 study evaluating ad

Collaboration and License Agreement, dated May 28, 2021, by and among the Company and Zai Lab (Hong Kong) Limited.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registrant as

Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates SAN DIEGO ? August 5, 2021 ? Mirati Therapeutics, Inc.

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiary Country of Origin MethylGene Inc. Canada Mirati Therapeutics B.V. Netherlands

Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates SAN DIEGO ? August 5, 2021 ? Mirati Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emplo

CALCULATION OF REGISTRATION FEE Title of Class of Securities to be Registered Number of Shares to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee Common Stock, par

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257636 CALCULATION OF REGISTRATION FEE Title of Class of Securities to be Registered Number of Shares to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee Common Stock, par value $0.001 per share, issuable upon exercise of pre-funded warrants 7

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emplo

Amended and Restated Sales Agreement, dated July 2, 2021, by and between Mirati Therapeutics, Inc. and Cowen and Company, LLC

EXHIBIT 1.2 MIRATI THERAPEUTICS, INC. $500,000,000 COMMON STOCK AMENDED AND RESTATED SALES AGREEMENT July 2, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to that certain Sales Agreement, entered into as of July 2, 2020 (the ?Original Sales Agreement?), by and between Mirati Therapeutics, Inc. (the ?Company?) and Cowen and Company, LLC

Form of Preferred Stock Warrant Agreement and Warrant Certificate

EXHIBIT 4.3 MIRATI THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 MIRATI THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between MIRATI THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking association] organized and e

As filed with the Securities and Exchange Commission on July 2, 2021

As filed with the Securities and Exchange Commission on July 2, 2021 Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

As filed with the Securities and Exchange Commission on July 2, 2021

Table of Contents As filed with the Securities and Exchange Commission on July 2, 2021 Registration No.

Form of Indenture, between Registrant and one or more trustees to be named

EXHIBIT 4.7 MIRATI THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 S

Form of Debt Securities Warrant Agreement and Warrant Certificate

EXHIBIT 4.6 MIRATI THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 MIRATI THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between MIRATI THERAPEUTICS, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] org

Form of Common Stock Warrant Agreement and Warrant Certificate

EXHIBIT 4.2 MIRATI THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 MIRATI THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between MIRATI THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking association] organized and existing u

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employ

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

Exhibit 99.1 Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China ? Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan ? Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-perc

MIRATI THERAPEUTICS, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 8, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 21, 2013 AMENDED AND APPROVED BY THE BOARD: APRIL 3, 2014 APPROVED BY THE STOCKHOLDERS: MAY 21, 2014 AMENDED AND AP

Exhibit 99.1 MIRATI THERAPEUTICS, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 8, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 21, 2013 AMENDED AND APPROVED BY THE BOARD: APRIL 3, 2014 APPROVED BY THE STOCKHOLDERS: MAY 21, 2014 AMENDED AND APPROVED BY THE BOARD: MARCH 25, 2015 APPROVED BY THE STOCKHOLDERS: MAY 21, 2015 AMENDED AND APPROVED BY THE BOARD: SEPTEMBER 12, 2016 AMEN

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Employer

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact Name of Registrant as

2020, by and between the Registrant and

SECOND AMENDMENT TO LETTER AGREEMENT This Second Amendment to Letter Agreement (the ?Amendment?) is entered into by Mirati Therapeutics, Inc.

Second Amendment to Letter Agreement, effective December 31, 2020, by and between the Registrant and Dr. James Christensen.

SECOND AMENDMENT TO LETTER AGREEMENT This Second Amendment to Letter Agreement (the ?Amendment?) is entered into by Mirati Therapeutics, Inc.

Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates

Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates ?Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents ?Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 ?Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor SAN DIEGO ? May 6, 2021 ? Mirati Therapeutics, Inc.

definitive proxy statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emplo

Seventh Amendment to Lease to 9393 Towne Centre, dated November 30, 2020

738896632.6 1 SEVENTH AMENDMENT TO LEASE AGREEMENT THIS SEVENTH AMENDMENT TO LEASE AGREEMENT (this ?Seventh Amendment?) is made as of November 30, 2020, by and between ARE-SD REGION NO. 20, LLC, a Delaware limited liability company (?Landlord?), and MIRATI THERAPEUTICS, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of Ju

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Em

Letter Agreement, dated December 18, 2019, by and between the Registrant and Benjamin Hickey.

December 18, 2019 Benjamin Hickey Re: Offer of Employment Dear Ben Mirati Therapeutics, Inc.

Letter Agreement, dated December 20, 2019, by and between the Registrant and Dan Faga.

December 20, 2019 Daniel Faga Re: Offer of Employment Dear Dan: Mirati Therapeutics, Inc.

Exhibit 4.5

DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Mirati Therapeutics, Inc.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-15803 MIRATI THERAPEU

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiary Country of Origin MethylGene Inc. Canada

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.16 MIRATI THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: SEPTEMBER 9, 2014 EFFECTIVE DATE: SEPTEMBER 9, 2014 AMENDED AND RESTATED: DECEMBER 9, 2015 AMENDED AND RESTATED: MARCH 30, 2017 AMENDED AND RESTATED: JANUARY 18, 2018 AMENDED AND RESTATED: JANUARY 17, 2019 AMENDED AND RESTATED: DECEMBER 12, 2019 AMENDED AND RESTATED: DECEMBER 10, 2020 Ea

MIRATI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

MIRATI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES SAN DIEGO ? February 25, 2021 - Mirati Therapeutics, Inc.

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 60468T 105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Mirati Therapeutics, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Mirati Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 60468T105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Mirati Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 60468T105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development pl

EX-99.1 J.P. Morgan Healthcare Conference January 11, 2021 Exhibit 99.1 This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, includ

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35921 Mirati Therapeutics, Inc. (Exact

MIRATI THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

MIRATI THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS SAN DIEGO - November 4, 2020 - Mirati Therapeutics, Inc.

Sixth Amendment to Lease to 9393 Towne Centre Drive, dated July 15, 2020

ex102alexandriarealestat DocuSign Envelope ID: AAA2986A-8994-4E12-B52E-A820E5BB0F56 SIXTH AMENDMENT TO LEASE AGREEMENT THIS SIXTH AMENDMENT TO LEASE AGREEMENT (this “Sixth Amendment”) is made as of July 15, 2020, by and between ARE-SD REGION NO.

Fifth Amendment to Lease to 9393 Towne Centre Drive, dated March 4, 2020

ex101alexandriarealestat FIFTH AMENDMENT TO LEASE AGREEMENT IY)a.rc,k THIS FIFTH AMENDMENT TO LEASE AGREEMENT (this "Fifth Amendment") 1s made as of ..EQbrual)' LJ,,, 2020, by and between ARE-SD REGION NO. 20, LLC, a Delaware l1m1ted hab11ity company ("Landlord\ and MIRA Tl THERAPEUTICS, INC., a Delaware corporation ("Tenant") RECITALS A. Landlord and Tenant entered mto that certain Lease Agreemen

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Mirati Therapeutics, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Mirati Therapeutics, Inc. and further agree that this Joint Filing Agreemen

MRTX / Mirati Therapeutics, Inc. / Boxer Capital, LLC - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

EX-99.1 Exhibit 99.1 MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, October 26, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering. In addition, Mirati

MIRATI THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

EX-99.2 Exhibit 99.2 MIRATI THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, October 27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shar

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par valu

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-227209 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par value per share 4,985,706(1) $202.00 $1,007,112,612 $109,875.99 (1) I

Underwriting Agreement, dated October 27, 2020.

EX-1.1 Exhibit 1.1 4,335,397 Shares of Common Stock MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT October 27, 2020 Goldman Sachs & Co. LLC SVB Leerink LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several underwriters c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2020 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 MIRATI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35921 46-2693615 (State of incorporation) (Commission File No.) (IRS Emp

Sponsored Research (Paid to Institution): AstraZeneca; Boehringer-Ingelheim; Calithera Bioeciences; EMD Serono; Roche/Genentech; GlaxoSmithKline; Gritstone Oncology; Guardant Health; Incyte; Janssen R&D; Eli Lilly and Company; Merck; Novartis; Pfizer

EX-99.2 Melissa L. Johnson1; Sai-Hong Ignatius Ou2; Minal Barve3; Igor I. Rybkin4; Kyriakos P. Papadopoulos5; Ticiana A. Leal6; Karen Velastegui7; James G. Christensen7; Thian Kheoh7; Richard C. Chao7; Jared Weiss8 KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients With Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRASG12C Mutation 1Sarah Cannon Research Institute Tenn